ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 157 filers reported holding ASCENDIS PHARMA A/S in Q2 2020. The put-call ratio across all filers is 0.39 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,051,075 | -1.4% | 139,375 | -6.1% | 0.09% | -4.2% |
| Q2 2023 | $13,242,469 | -46.4% | 148,375 | -40.7% | 0.10% | -43.9% |
| Q1 2023 | $24,709,105 | +6.3% | 250,375 | +31.5% | 0.17% | +8.9% |
| Q4 2022 | $23,249,409 | +9.1% | 190,375 | -7.8% | 0.16% | +4.7% |
| Q3 2022 | $21,311,000 | +3.9% | 206,375 | -6.5% | 0.15% | -11.2% |
| Q2 2022 | $20,520,000 | +6.4% | 220,751 | +34.3% | 0.17% | +29.0% |
| Q1 2022 | $19,283,000 | -39.9% | 164,318 | -31.1% | 0.13% | -36.1% |
| Q4 2021 | $32,075,000 | -19.6% | 238,422 | -4.8% | 0.20% | -24.4% |
| Q3 2021 | $39,909,000 | +7.2% | 250,399 | -11.5% | 0.27% | +6.3% |
| Q2 2021 | $37,226,000 | -3.4% | 282,980 | +17.6% | 0.26% | -20.6% |
| Q1 2021 | $38,556,000 | -3.9% | 240,671 | 0.0% | 0.32% | +0.9% |
| Q4 2020 | $40,141,000 | -3.3% | 240,671 | -10.6% | 0.32% | -18.5% |
| Q3 2020 | $41,523,000 | +47.7% | 269,079 | +41.6% | 0.39% | +31.3% |
| Q2 2020 | $28,114,000 | +84.6% | 190,079 | +69.7% | 0.30% | +75.7% |
| Q1 2020 | $15,232,000 | -2.2% | 112,000 | 0.0% | 0.17% | +1.2% |
| Q4 2019 | $15,581,000 | +72.1% | 112,000 | +19.1% | 0.17% | +39.2% |
| Q3 2019 | $9,054,000 | – | 94,000 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |